ACI
NKTR icon

AMP Capital Investors’s Nektar Therapeutics NKTR Stock Holding History

AMP Capital Investors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,820
Closed -$758K – 1229
2019
Q3 		$758K Sell
2,820
-100
-3% -$36.7K ﹤0.01% 915
2019
Q2 		$1.52M Sell
2,920
-406
-12% -$204K 0.01% 819
2019
Q1 		$1.63M Sell
3,326
-75
-2% -$44.4K 0.01% 787
2018
Q4 		$1.72M Sell
3,401
-1,698
-33% -$1.02M 0.01% 750
2018
Q3 		$4.66M Buy
5,099
+2,691
+112% +$2.3M 0.03% 566
2018
Q2 		$1.76M Buy
+2,408
New +$2.78M 0.01% 789

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

AMP Capital Investors's NKTR Position: Q4 2019 in Review

AMP Capital Investors sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 2,820 shares — an estimated $758K sold.

AMP Capital Investors first reported a position in NKTR in Q2 2018 and held it in 6 quarters. The position peaked at $4.66M in Q3 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • AMP Capital Investors reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • AMP Capital Investors sold 2,820 Nektar Therapeutics shares in Q4 2019, an estimated $758K.
  • AMP Capital Investors first reported a position in Nektar Therapeutics in Q2 2018 and held it in 6 quarters.
  • AMP Capital Investors's Nektar Therapeutics position peaked at $4.66M in Q3 2018.
  • 281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on AMP Capital Investors's 13F filing for Q4 2019, filed 13 Feb 2020.